<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Jendle, Johan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dulaglutide Reduces HbA1c More Than Glargine When Used in Combination with Prandial Insulin</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results from the Assessment of Weekly Administration of LY2189265 in Diabetes-4 trial [AWARD-4; NCT01191268], which indicate that dulaglutide, in combination with insulin lispro, is an effective and safe option for treatment intensification in type 2 diabetes patients who are inadequately controlled on 1 or 2 doses of insulin.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>